96 patents
Page 3 of 5
Utility
Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
5 Apr 22
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
Filed: 14 Sep 18
Utility
Activating Pyruvate Kinase R
24 Mar 22
The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Sanjeev Forsyth, Patrick F. Kelly, Madhu Mondal, Maria Ribadeneira, Patricia Schroeder
Filed: 17 Sep 21
Utility
Bromodomain Inhibitors for Androgen Receptor-driven Cancers
24 Mar 22
Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed.
Sylvie GUICHARD, Maureen CALIGIURI, Anna ERICSSON, Qunli XU, Hesham MOHAMED
Filed: 23 Sep 21
Utility
Inhibiting Cyclic Amp-responsive Element-binding Protein (Creb) Binding Protein (CBP)
24 Mar 22
The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I).
George LUKE, Suresh BABU
Filed: 23 Sep 21
Utility
Compositions for Inhibiting Ubiquitin Specific Protease 1
10 Mar 22
This disclosure relates to modulating ubiquitin specific protease 1 (USP1) and provides novel chemical compounds useful as inhibitors of USP1, as well as various uses of these compounds.
Alexandre Joseph Buckmelter, Justin Andrew Caravella, Jian Lin, Edward L. Fritzen
Filed: 27 Dec 19
Utility
Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
8 Mar 22
George P. Luke, Stephen Hubbs, Matthew W. Martin, Shawn E. R. Schiller, Robert Wenslow, Yawei Shi, Jun Huang
Filed: 28 Aug 20
Utility
Inhibiting CREB binding protein (CBP)
22 Feb 22
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson
Filed: 8 Jun 20
Utility
Inhibiting ubiquitin specific peptidase 30
15 Feb 22
Justin Caravella, Bingsong Han, Cuixian Liu, Stephanos Ioannidis, Alexandre Joseph Buckmelter, David James Richard, Matthew W. Martin, Steven Mischke, Scot Mente
Filed: 5 Oct 18
Utility
Inhibiting Ubiquitin Specific Peptidase 9X
10 Feb 22
FLT3-ITD and FLT3-TKD are the most frequent mutations in acute myeloid leukemia (AML) with the former associated with a poor prognosis.
Bruce Follows, Adam Charles Talbot, Scot Mente, Sabine Ruppel, Tatiana Shelekhin, Katherine J. Kayser-Bricker
Filed: 26 Dec 19
Utility
Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound
3 Feb 22
Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD).
Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Gary MARSHALL, Lorna MITCHELL, David RICHARD, Zhongguo WANG, Sanjeev FORSYTH, Patrick F. KELLY, Madhu MONDAL, Maria RIBADENEIRA, Patricia SCHROEDER
Filed: 19 Sep 19
Utility
Fused Pyrrolines Which Act As Ubiquitin-specific Protease 30 (USP30) Inhibitors
18 Nov 21
Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
Filed: 4 Oct 19
Utility
Inhibiting Ubiquitin Specific Peptidase 9X
11 Nov 21
This disclosure provides methods of treating cancer with an inhibitor of ubiquitin specific peptidase 9X alone or in combination with an immune checkpoint pathway inhibitor.
Maureen LYNES, Weiping WANG, Bruce FOLLOWS, Katherine J. KAYSER-BRICKER, Adam Charles TALBOT, Scot MENTE, Tatiana SHELEKHIN, Anna ERICSSON
Filed: 19 Sep 19
Utility
Purinones as ubiquitin-specific protease 1 inhibitors
2 Nov 21
Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin A. Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
Filed: 14 Aug 19
Utility
Activating Pyruvate Kinase R
7 Oct 21
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
Filed: 18 Jun 21
Utility
Tetrahydroquinoline compositions as BET bromodomain inhibitors
7 Sep 21
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
Filed: 28 Jan 20
Utility
Salts of (S)-(5-CYCLOBUTOXY-2-METHYL-6-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)-3,4-DIHYDROQUINOLIN-1(2H)-YL)(CYCLOPROPYL)METHANONE and Solid Forms Thereof
26 Aug 21
The present disclosure reports salts of (S)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)(cyclopropyl)methanone, solid forms thereof, and methods of making and using the same.
George P. Luke
Filed: 28 Jun 19
Utility
Treatment of Glioblastoma with Fasn Inhibitors
19 Aug 21
The present disclosure relates to methods of treating glioblastoma by administering to a patient in need thereof a FASN inhibitor.
Wei LU, Matthew W. MARTIN, Erik WILKER, Howard FINE
Filed: 25 Oct 18
Utility
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
12 Aug 21
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Susan ASHWELL, Blythe THOMSON, Patrick F. KELLY, Alan COLLIS, Jeff DAVIS, Duncan WALKER, Wei LU
Filed: 28 Apr 21
Utility
Pyrrolopyrrole Compositions As Pyruvate Kinase (PKR) Activators
12 Aug 21
The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds.
Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
Filed: 23 Apr 21
Utility
Benzopiperazine compositions as BET bromodomain inhibitors
10 Aug 21
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
Filed: 12 May 20